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PERSPECTIVE

Developmental transcription factors
in age-related CNS disease: a phoenix
rising from the ashes?
Few would doubt that understanding the developmental landscape
from which a mature neuron is derived is essential to understand
its biology. The temporal and spatial position of a cell from the very
earliest stages of development predicts the unique combinations of
growth factors it will subsequently be exposed to. This combination
of factors determines the transcriptional platform set within the
cell by its specific combination of transcription factors, who direct
the show. This, in turn, determines what cell type it will differentiate into, and what connections it will make. How this developmental platform translates to maintenance of a differentiated neuron in
an adult brain is less clear.
Most developmental factors control aspects of biology that are
not required, or even wanted, during or after the differentiation
process: initiators of DNA synthesis or proliferation are clearly of
no use to a differentiated neuron, and can certainly evoke damaging effects.
So, why is it commonplace in the adult brain to see the upregulation of developmental factors during stress, trauma, and disease?
Two potential explanations dominate the debate. Firstly, that there
is a cellular attempt to rejuvenate (the “phoenix from the ashes”) by
using the only machinery it ‘knows’ how, or secondly, that, indeed,
these transcription factors are not simply ‘developmental’, and can
drive distinct platforms of transcription in different circumstances
(or “horse for many courses”). These two hypotheses are, of course,
not necessarily mutually exclusive.
Regardless of the ‘motive’ many developmental transcription
factor-encoding genes are recruited in difficult situations in later
life. One such beast is Pax6, the subject of some of our laboratory’s
research (Blake et al., 2008; Needhamsen et al., 2014; Thomas et al.,
2016).
The developmental transcription factor Pax6: The Pax6 gene
belongs to the highly functionally and structurally conserved Pax
gene family (Pax1–9) of tissue-specific transcription factors. The
Pax family are instrumental in development and have a critical role
in brain regionalisation and specification of subtypes of neurons
within brain regions. Pax6 is one of the earliest gene products expressed in the developing embryo. Initially, Pax6 is expressed in the
neural plate, and after closure of the neural tube it is expressed in
the lower ventral region except in the most ventral cells of the floor
plate, acting to ventrally polarize the neural tube.
Pax6 is a key neurogenic factor and a well-accepted neurogenic
determinant. Indeed, Pax6 is frequently used as a marker of neural
precursor status. Recent studies have demonstrated that overexpression of both Pax6 and another transcription factor, Sox2, is
sufficient to transdifferentiate fibroblast cells into induced neuronal
progenitors (Maucksch et al., 2012), in line with it having been
demonstrated that Pax6 alone induces neuronal specification of
postnatal forebrain astrocytes (Heins et al., 2002).
As well as specifying neural progenitor cells, Pax6 also acts in a
second phase of fate decision-making during development, namely
during the specification of a subpopulation of neurons. Within
the developing brain, Pax6 expression is confined to the forebrain,
optic vesicles and the ventral midbrain (Stoykova and Gruss, 1994).
Its expression correlates with the appearance of dopaminergic
neurons of the ventral thalamus (preoptic area, zona incerta and
periventricular and arcuate nuclei), the mesencephalic tegmentum
(region of the differentiating substantia nigra) as well as in neurons
of the dorsolateral part of the reticular substantia nigra (Stoykova
and Gruss, 1994; Vitalis et al., 2000).
Over-expression of Pax6 in a variety of cells and circumstanc64

es has provided compelling evidence for a potent role of Pax6 in
specifying dopamine producing neurons. Its over-expression in
embryonic day 12 rat ventral mesencephalon neural stem cells
yields significantly higher tyrosine hydroxylase-expressing neurons
compared to controls (Spitere et al., 2008). The forced expression
of Pax6 in rostral migratory stream neural precursors drives newly
generated periglomerular neurons to assume a tyrosine hydroxylase-positive dopaminergic identity in vivo (Hack et al., 2005).
Critically, Pax6-deficient neuroblasts transplanted into the subventricular zone of adult wild type mice maintain similar migratory
and neuronal differentiation capabilities but undergo precocious
differentiation resulting in cell fate switching and failure to generate specific dopaminergic neuronal sub-classes (Kohwi et al., 2005).
More research in this field is certainly required, as there are still
many anomalies to overcome, as Pax6 suppression has also been
shown to be beneficial in the generation of a dopaminergic phenotype from precursors (Denham et al., 2012).
In the adult brain: In the adult brain, Pax6 again rears its head, but
“only” in very specific locations. Very specific indeed, and in keeping with its developmental role – in areas of continued proliferation
and neurogenesis. Expression is maintained in adult neural progenitor cells of the subventricular zone of the olfactory bulb and the
subgranular zone of the dentate gyrus (Stoykova and Gruss, 1994).
The “only” in the earlier sentence is in quotation marks as it is neither the whole truth nor is it nothing but the truth. When people
have looked more exhaustively and in greater detail, isolated populations of Pax6-positive cells have been found. In the normal adult
brain Pax6 expression has also been demonstrated in areas that do
not undergo overt neurogenesis: the substantia nigra pars reticulata, retina, preoptic area, zona incerta, ventral tegmental area, and
mesencephalic periaqueductal gray (Stoykova and Gruss, 1994; Vitalis et al., 2000). Pax6 is also expressed within certain post-mitotic
cells of the adult substantia nigra in the human and rodent midbrain (Thomas et al., 2016). We have shown that, within the normal
aging human adult midbrain substantia nigra, a very small number
of cells express PAX6 protein. In the rat, many of these substantia
nigra Pax6-positive cells co-label with tyrosine hydroxylase – the
rate-limiting enzyme in the synthesis of dopamine and is expressed
in catecholaminergic neurons (White and Thomas, 2012); and thus
in this area of the adult brain, Pax6 is likely expressed in differentiated dopaminergic neurons. However not all Pax6-positive cells in
the substantia nigra also expressed tyrosine hydroxylase, and we did
not observe any co-labelling with astrocyte markers (glial fibrillary
acidic protein), so this avenue of exploration certainly requires further work to generate a comprehensive identity of these cells.
Disease and damage: In keeping with its role in developmental
neurogenesis, injury models have suggested that in these adult
regions Pax6 expression is associated with the generation of new
neurons in the areas of damage. For example a transient forebrain
ischemic brain injury induces Pax6 up-regulation in subgranularzonal cells (Nakatomi et al., 2002); treatment of a rat Parkinson’s
disease model with a dopamine receptor agonist increases proliferation and cell survival in newly generated neurons (Winner et al.,
2009) with concurrent increased expression of Pax6 in these cells;
a spinal cord injury results in transient up-regulation of Pax6 in
the ependymal layer (Yamamoto et al., 2001); and the number of
Pax6-positive cells is markedly increased in the subventricular zone
following striatal quinolinic acid-induced striatal cell death in rats
(Jones and Connor, 2011).
We have also recently shown that, in an animal model of Parkinson’s disease, the number of Pax6-positive cells within the midbrain
substantia nigra increases significantly (Thomas et al., 2016). We
used the well-characterized rat 6-hydroxydopamine striatal lesion
model and assessed the number of Pax6-positive cells in the substantia nigra at time points corresponding to the phase of active cell
loss (14 days post lesion) and after cell loss has plateaued (28 days
post lesion).
In this model, the number of Pax6-positive cells is significantly
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elevated during the phase of active cell loss, and this increase in
Pax6-positive cells is maintained after cell loss has completed. This
potentially indicates that the cells that upregulate Pax6 do not die
throughout this process, and as we have shown that many of these
Pax6-postive cells are differentiated dopaminergic neurons (tyrosine
hydroxylase-positive), then we believe this is indeed an interesting
finding warranting further investigation.
So what about the human disease ‘model’? We obtained post-mortem brain tissue of people who died with Parkinson’s disease and
have demonstrated that, in comparison to age and sex matched
controls, the small number of cells expressing PAX6 in the human
substantia nigra was significantly reduced.
So, what is it doing there? It seems that at least one important
role that is directed by Pax6 in these adult brain cells is to ensure
cell survival. Olfactory bulb neurons of 3 month old mice co-express Pax6 along with markers of terminal dopaminergic differentiation, including tyrosine hydroxylase and the dopamine transporter
(Ninkovic et al., 2010). The loss of Pax6 expression by Cre-Lox recombination results in these neurons undergoing apoptosis, showing that Pax6 is required for the survival of some of these neurons
(Ninkovic et al., 2010). Some of the genes targeted by Pax6 in this
process are known; for instance Pax6 mediates survival of olfactory
bulb neurons via crystallin αA and its loss reduces crystallin αA expression and induces apoptosis via caspase-3 activation (Ninkovic
et al., 2010).
We have also recently shown that PAX6 effectively promotes survival in a cell culture model of PD – human neuroblastoma-derived
SH-SY5Y cells differentiated down a dopaminergic lineage using
retinoic acid and then exposed to dopaminergic-neuron-selective
neurotoxins (rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). We induced expression of PAX6 after differentiation
in this cell culture model and then applied neurotoxic insults and
measured survival, apoptosis and mitochondrial depolarization.
PAX6 induction markedly improved how the cells fared in all
these parameters, indicating that PAX6 over-expression following
differentiation increases the survival of SH-SY5Y cells exposed to
dopaminergic-neuron-selective neurotoxins by increasing their
resistance to both programmed cell death and the effects of oxidative stress on mitochondrial health and function. It is worth
noting that we also observed a significant upregulation of another
developmental transcription factor gene known to play a role in the
differentiation and survival of midbrain dopaminergic neurons,
neurogenin 2, following PAX6 induction (Thomas et al., 2016).
It is intriguing to note that in Parkinson’s disease, the two substantia nigra areas, the pars compacta and the pars reticulata do not
share equal vulnerability to developing pathology; the substantia
nigra pars compacta experiences the highest levels of degeneration,
with the substantia nigra pars reticulata degenerating later as the
disease progresses. As we have shown, Pax6 expression occurs in the
substantia nigra pars reticulata, which could imply a role for Pax6
in the protection of these dopamine-producing cells. Importantly
then, Pax6 may have a third function in promoting cell maintenance and/or survival of adult neurons (Blake et al., 2008).
Conclusion: The phoenix of Greek mythology is a long-lived bird
that is cyclically regenerated or reborn, obtaining new life by arising
from the ashes of its predecessor. We do not know the precise function of our ‘phoenix’ developmental transcription factors in the
neurobiology of aging brains of humans yet, but it is not entirely
unlikely that one day we will use them to enable rebirth within the
ashes of the degenerating central nervous system.
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We dedicate this work to the memory of the wonderful Oliver Sacks
R.I.P. May his legacy continue to awaken the minds of readers for
many years to come.
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